Related Experiment Video
Updated: Apr 23, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
1.1K
Targeting FLT3 to treat leukemia
1Johns Hopkins University, Medical Oncology , 1650 Orleans Street, Baltimore, MD , USA.
Expert Opinion on Therapeutic Targets
|September 19, 2014
Summary
FLT3 inhibitors show promise for acute myeloid leukemia (AML) but face challenges like off-target effects and resistance. Combining FLT3 inhibitors with other therapies may improve outcomes for FLT3-mutated AML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- FLT3 mutations, specifically internal tandem duplications (ITD), are present in ~23% of AML patients under 60 and are linked to poor prognosis.
- FLT3 overexpression in AML necessitates targeted therapeutic strategies.
- Despite extensive research, no FLT3 inhibitors have FDA approval for AML due to off-target effects and resistance.
Purpose of the Study:
- To review FLT3 inhibitors investigated for AML treatment.
- To discuss current therapeutic approaches and strategies for incorporating FLT3 inhibitors into AML therapy.
Main Methods:
- Review of preclinical and clinical studies on FLT3 inhibitors.
- Analysis of current treatment paradigms for FLT3-mutated AML.
- Discussion of resistance mechanisms and combination strategies.
Main Results:
- Several FLT3 kinase inhibitors have been explored, but none are FDA-approved for AML.
- Off-target effects and acquired resistance limit the efficacy of current FLT3 inhibitors.
- Combination therapies are emerging as a promising strategy.
Conclusions:
- Combining FLT3 inhibitors with chemotherapy, epigenetic modifiers, or downstream effector inhibitors may enhance treatment outcomes.
- Future tailored treatments for FLT3-mutated AML require novel clinical trials with aligned research goals.
- Developing effective FLT3-targeted therapies necessitates addressing resistance and off-target toxicities.
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K